enGene Therapeutics Inc. (ENGN) — Dilution Risk Analysis

Current Snapshot

enGene Therapeutics Inc. (ENGN) has a DilutionWatch score of 64/10 and is classified as HIGH risk. The score date in the source data is 2026-10-03T03:45:52.527348.

This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.

Share Structure

Shares Outstanding
67,016,316 Source
Public Float
22,487,024 Source
Float as % of Outstanding
33.6%

Dilution Risk Score

Score: 64/10 Source (as of 2026-10-03T03:45:52.527348)

Recent SEC Filings

2 shelf registration or ATM offering filings detected in recent history.

Recent filing forms in the source payload: XBRL 1, 8-K 1, 424B5 1, EFFECT 1, S-3 1, 4 5.

FormFiledAccession
xbrl 2026-07-31 xbrl-3785-xbrl_warrant
8-K 2026-03-09 0001193125-26-097546
424B5 2026-03-09 0001193125-26-097563
EFFECT 2026-03-02 9999999995-26-000700
S-3 2026-02-19 0001193125-26-059479
4 2026-02-03 0000929638-26-000477
4 2026-02-03 0000929638-26-000478
4 2026-02-03 0000929638-26-000479
4 2026-02-03 0000929638-26-000481
4 2026-02-03 0000929638-26-000482

Dilution Risk Drivers

DriverStored ValueSource
Shelf registration capacity $400,000,000 Source
ATM offering capacity remaining $100,000,000 Source
Cash runway 46 months Source
Three-year share count growth 188.89% Source

DilutionWatch Analysis

Risk Level
HIGH (Score: 64/10) Source
Cash Runway
46 months Source
ATM Offering Capacity Remaining
$100,000,000 Source
Shelf Registration Capacity
$400,000,000 Source
Share Count Growth (3-Year)
188.89% Source

What This Page Does Not Estimate

DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.

Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.